New Retina Radio by Eyetube

18-month results for GATHER1 look promising, but another pivotal study is still in the works. What else needs to happen for Zimura to become the first FDA-approved therapy for geographic atrophy? New Retina Radio spoke with Veeral Sheth, MD, about what he shared regarding the GATHER1 study at this year’s ARVO meeting. We also spoke with Matthew Starr, MD, about his research on the development of C...

The phase 3 TENAYA and LUCERNE trials, which assessed the safety and efficacy of faricimab for wet AMD therapy, have wrapped up. What did the researchers learn? New Retina Radio spoke with Arshad Khanani, MD, MA, about his ARVO presentation on these trials. We also spoke with David Lally, MD, whose ARVO presentation adds new data to the great fluid debates in wet AMD. What did his research team un...

Need a refresher on Protocol W, the latest study from the DRCR Retina Network? Yoshi Yonekawa, MD, invites VBS members Ajay Kuriyan, MD; Anton Orlin, MD; and Paula Pecen, MD, to review the data from Protocol W and to discuss how the study may change their practice patterns.  This editorially independent podcast is supported with advertising.

In the second part of this two-part series on literature in retinal detachment surgery, moderator Jay Sridhar, MD, is joined by panelists Brian Do, MD; Sabin Dang, MD; and Avni Finn, MD, MBA, to discuss a pair of recently published reports. The panel reviews an article on the outcomes of primary RRD repair with extensive scleral-depressed vitreous and dynamic examination, as well as a report on 36...

In the first part of this two-part series reviewing reports from the Primary Retinal Detachment Outcomes Study Group, moderator Jay Sridhar, MD, invites panelists Brian Do, MD; Sabin Dang, MD; and Avni Finn, MD, MBA, to dissect a trio of papers. They discuss the results of studies examining retinal detachment surgery outcomes in phakic and pseudophakic patients. After the break, the panel summariz...

Early phase data sets are one of the stars of the Angiogenesis, Exudation, and Degeneration annual meeting. Which presentations are worth a second look? John Kitchens, MD, is joined by Nadia Waheed, MD, and Charles Wykoff, MD, PhD, as they share data from their respective presentations showcased at this year’s meeting. After the break, Drs. Kitchens, Waheed, and Wykoff chat what these early phase...

Which upcoming therapies will extend duration for patients with wet AMD? John Kitchens, MD, sits down with Diana Do, MD, and Carl Regillo, MD, to hear about their presentations at this year’s Angiogenesis, Exudation, and Degeneration annual meeting. After the break, Drs. Kitchens, Do, and Regillo discuss how the future of wet AMD therapies may alter clinical care for patients undergoing treatment....

Can OCT be used to detect areas at risk for GA progression in patients with intermediate AMD? Yoshihiro Yonekawa, MD, invites Marion Munk, MD, PhD; Lejla Vajzovic, MD; and David Xu, MD, to discuss a paper published by the AREDS2 Group on this topic. They explore the researchers' findings and discuss the clinical implications of the study's results. This editorially independent podcast is supported...

How close are retina specialists to offering an effective therapy for patients with geographic atrophy secondary to dry AMD? John Kitchens, MD, hears summaries of two talks from Pravin Dugel, MD, and SriniVas Sadda, MD, from this year’s Angiogenesis, Exudation, and Degeneration meeting. After the break, Dr. Kitchens moderates a discussion about the nuances of bringing treatments in this disease to...

In this roundtable hosted by María H. Berrocal, MD, and Audina M. Berrocal, MD, new department chairs in retina share their journeys to leadership and how to move the needle on diversity in the field. Participants include Sophie J. Bakri, MD, MBA; R.V. Paul Chan, MD, MSc, MBA, FACS; and Shlomit Schaal, MD, PhD, MHCM.  This editorially independent podcast is supported with advertising.

Aleksandra Rachitskaya, MD, moderates a panel comprised of Mrinali Gupta, MD; Eric Nudleman, MD, PhD; and Aris Thanos, MD, to review a study from the DRCR Retina Network that compared intravitreal aflibercept (Eylea, Regeneron) to vitrectomy with panretinal photocoagulation for the treatment of vitreous hemorrhage secondary to proliferative diabetic retinopathy. The group summarizes the study and...

Aleksandra Rachitskaya, MD, leads a discussion with Mrinali Gupta, MD; Eric Nudleman, MD, PhD; and Aris Thanos, MD, about the phase 2 LADDER study, which evaluated the Port Delivery System With Ranibizumab (Genentech) in patients with wet AMD. Listen to a summary of the study and a thorough discussion of its implications with this group of Vit-Buckle Society members.  This editorially independent...

In this podcast, Prof. Richard Harrad (UK) joins Prof. Ben Thompson (Canada) and Prof. Ann Webber (Australia) for a discussion on the use of dichoptic therapy in the management of amblyopia. In this episode, we consider the limitations of the current clinical approach to amblyopia before discussing dichoptic therapy, a new and innovative technology with the potential to address some of the unmet n...

In this podcast, Dr Peter Kaiser (USA) leads a conversation with Prof. James Wolffsohn (UK) and Dr Pearce Keane (UK) in which they explore the use of AI technology in clinical practice and how it may lead to changes in the management of patients. Considering both the front and the back of the eye, the faculty discuss current and potential future uses of AI in ophthalmology and optometry, the chall...

Will data shared at AAO 2020 affect your clinical decision-making with wet AMD patients? Rishi Singh, MD, invites Justis Ehlers, MD, and Mark Gillies, MD, PhD, to review their presentations from AAO 2020 and discuss how clinical practice may be affected by their new information. Dr. Ehlers presented data on fluid volatility and the software used to measure it, and Dr. Gillies examined a 10-year da...

Join Dr. Rishi Singh (USA) as he speaks with Prof. Jennifer Arnold (Australia), Prof. Mark Gillies (Australia) and Dr. SriniVas Sadda (USA) about the role and importance of fluid in the management of retinal diseases. In this episode, we will look at the different fluid compartments and our current understanding of their relevance to neovascular AMD. We will discuss the learnings gained from the H...

Host Jorge Fortun, MD, and guests Cynthia Qian, MD; Christina Weng, MD, MBA; and Basil Williams, MD, review real-world data that compare widefield swept-source OCT angiography with ultra-widefield color fundus photography and fluorescein angiography for the detection disease activity in patients with diabetic retinopathy. This editorially independent podcast is supported with advertising.

Host Jorge Fortun, MD, and guests Cynthia Qian, MD; Christina Weng, MD, MBA; and Basil Williams, MD, discuss a retrospective study on the efficacy and safety of an intravitreal dexamethasone implant (Ozurdex, Allergan) in patients with diabetic macular edema. They review the top-line data and study design of this real-world report. This editorially independent podcast is supported with advertising...

How will data shared at AAO 2020 impact clinical decision-making in wet AMD therapy? Rishi Singh, MD, is joined by Diana Do, MD, and Jeffrey Heier, MD, to review their talks from the AAO 2020 meeting and to see how their data might influence the day-to-day work of clinicians in retina. Dr. Do presented a meta-analysis comparing all anti-VEGF agents and regimens for the treatment of wet AMD, and Dr...

DRCR Retina Network Protocol AB compared aflibercept (Eylea, Regeneron) to PPV and PRP in patients with diabetic vitreous hemorrhage. DRCR Retina Network Vice Chair and Protocol AB chair Andrew Antoszyk, MD, joins NRR to review the study’s findings, which were presented at this year’s AAO Annual Meeting.  This editorially independent podcast is supported with advertising.

Tracking real-world data on geographic atrophy has been patchwork process—until now. Thanks to the AAO IRIS Registry, real-world information on eye diseases can be gathered and assessed. What was found in the IRIS Registry regarding GA, and how will it change the way you practice? Ehsan Rahimy, MD, outlines how he and his team identified patients and trends, and summarizes how he applied the group...

In 2021, E/M codes will undergo their most significant changes since 1997. How will these changes affect your billing and coding—and what processes can you put in place to get ahead of the game? AAO Coding and Practice Management Executive Joy Woodke informs us of the changes ahead, which were shared at this year’s AAO Annual Meeting.  This editorially independent podcast is supported with adverti...

The next generation of therapy for DME patients will require looking beyond the VEGF pathway. In the phase 2 BOULEVARD study, researchers are assessing the safety and efficacy of the angiopoietin-2 mediator faricimab (Roche/Genentech) for the treatment of DME. Could the angiopoietin pathway present a new option for patients? Karl Csaky, MD, PhD, sits down with NRR to review data from the study, wh...

Retinal arteriolar macroaneurysm (RAM) usually regresses spontaneously, but can lead to irreversible vision loss if regression does not occur. Could anti-VEGF therapy be an option for these patients? J. Fernando Arevalo, MD, PhD, joins NRR to discuss data from a study that asked that question. He presented the data at this year’s AAO Annual Meeting.  This editorially independent podcast is support...

The burden of anti-VEGF therapy is particularly high in DME patients, many of whom are young, in the workforce, and unable to easily maintain monthly therapy. Could the antibody biopolymer conjugate KSI-301 (Kodiak Sciences) alleviate that burden while maintaining the outcomes experienced with anti-VEGF therapy? Arshad M. Khanani, MD, MA, shares the results of the phase 1B, long-term, multidose st...